Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03417544 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
A Phase 2 study of HER2-positive Metastatic Breast Cancer and Central Nervous System Metastases, sponsored by Nancy Lin, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT03417544 is a Phase 2 study of HER2-positive Metastatic Breast Cancer and Central Nervous System Metastases that is active but no longer recruiting, run by Nancy Lin, MD. The registered enrollment target is 19 participants, below the 122-participant average among 11 other HER2-positive Metastatic Breast Cancer trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03417544, a Phase 2 study of HER2-positive Metastatic Breast Cancer and Central Nervous System Metastases, is active but no longer recruiting, sponsored by Nancy Lin, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain. The names of the study drugs involved in this study are: * Atezolizumab * Pertuzumab * Trastuzumab
Conditions Studied
Interventions
- DRUG ATEZOLIZUMAB
- DRUG PERTUZUMAB
- DRUG TRASTUZUMAB
Study Locations (2)
Illinois
- Northwestern University - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03417544
The ClinicalTrials.gov registry entry for NCT03417544 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 122-participant average among 11 other HER2-positive Metastatic Breast Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Nancy Lin, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HER2-positive Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which ATEZOLIZUMAB is the first listed.
NCT03417544 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03417544 about?
NCT03417544 is a clinical study titled "Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC". This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain. The names of the study drugs involved in this study are: * Atezolizumab * Pertuzumab * Trastuzumab
What is the current status of trial NCT03417544?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2018-05-21. Estimated completion is 2025-12.
What conditions does trial NCT03417544 study?
This clinical trial studies the following conditions: HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases.
What interventions are being tested in trial NCT03417544?
The interventions under investigation include: ATEZOLIZUMAB (DRUG), PERTUZUMAB (DRUG), TRASTUZUMAB (DRUG).
Who is sponsoring clinical trial NCT03417544?
This trial is sponsored by Nancy Lin, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03417544 being conducted?
This trial has 2 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
ACTIVE NOT RECRUITING · Phase 2
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
RECRUITING · NA
-
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
RECRUITING
-
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
ACTIVE NOT RECRUITING
Explore more on PlainTrial
HER2-positive Metastatic Breast Cancer
All registered trials for this condition
Central Nervous System Metastases
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.